Ixabepilone for locally advanced or metastatic breast cancer
Please note that following on from information provided to NICE by the company in December 2008, the appraisal of Ixabepilone for locally advanced or metastatic breast cancer [ID377] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 377
Referral date 01 December 2007
Topic area
  • Cancer

Provisional Schedule

Closing date for invited submissions / evidence submission: 02 October 2008
1st appraisal committee meeting: TBC

Project Team

Communications manager: Sarita Tamber
Executive Lead: Gillian Leng
Project manager: Laura Malone
Technical Lead: Helen Tucker

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
20 January 2023 Discontinued. Please note that following on from information provided to NICE by the company in December 2008, the appraisal of Ixabepilone for locally advanced or metastatic breast cancer [ID377] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
9 December 2008 The manufacturer recently received a negative CHMP opinion for Ixabepilone for locally advanced or metastatic breast cancer. Consequently this appraisal will be suspended until we receive an update from the manufacturer on the status of regulatory approval.

For further information on our processes and methods, please see our CHTE processes and methods manual